Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

in castrate resistant prostate cancer in 2010, and a third Phase III trial in non-small cell lung cancer in early 2011. OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals ( ISIS), to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities, the potential benefits of our product candidates, our key 2010 objectives, expectations regarding accrual of clinical trials and timing of release of results of studies, and our anticipated future expenses, revenues, reimbursements, capital and sufficiency of capital. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a num
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... never heard of "graphene" before, you might know something about ... announcements. Two physicists at the University of Manchester (UK) ... regarding the two-dimensional material graphene," carbon flakes that are only ... steel and as conductive as copper. But, what happens ...
... Oct. 13 Osteotech, Inc. (Nasdaq: OSTE ... products for regenerative healing, announced today that it has ... Trade Commission granted early termination of the Hart-Scott-Rodino waiting ... closing of the merger remains subject to antitrust clearance ...
... Today From a Preventable Lung Disease -- LONDON, October 14, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Beyond the Nobel Prize, what's next for graphene? 2Osteotech Announces Early Termination of HSR Waiting Period 2550 People Across Europe Will Die Today From a Preventable Lung Disease 2550 People Across Europe Will Die Today From a Preventable Lung Disease 3550 People Across Europe Will Die Today From a Preventable Lung Disease 4550 People Across Europe Will Die Today From a Preventable Lung Disease 5550 People Across Europe Will Die Today From a Preventable Lung Disease 6550 People Across Europe Will Die Today From a Preventable Lung Disease 7550 People Across Europe Will Die Today From a Preventable Lung Disease 8550 People Across Europe Will Die Today From a Preventable Lung Disease 9
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 2011) - A new study has found that most patients ... recommended number of samples to diagnose celiac disease. The ... Endoscopy , analyzed a national database of biopsy specimens maintained ... patients had a biopsy of the small intestine, but only ...
... leaves can vary by a factor of 1,000 across plant species, ... new study by an international team of scientists led by UCLA ... In research federally funded by the National Science Foundation, the ... to dry soil because of their distinct vein systems. ...
... The Damon Runyon Cancer Research Foundation, a ... researchers, named 18 new Damon Runyon Fellows at ... recipients of this prestigious, three-year award are outstanding ... in the laboratories of leading senior investigators across ...
Cached Biology News:Low adherence to biopsy guidelines affects celiac disease diagnosis in the United States 2Being small has its advantages, if you are a leaf 2Being small has its advantages, if you are a leaf 3Being small has its advantages, if you are a leaf 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6
... Mouse P815 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... Streptavidin-HRP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
Biology Products: